Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems

References

• Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 2013;31:1592–605.
   PubMed Web of Science ®Google Scholar
• Tong R, Kohane DS. New strategies in cancer nanomedicine. Annu Rev Pharmacol Toxicol 2016;56:41–57.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Shotorbani SS, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull 2014;4:313–21.
   PubMedGoogle Scholar
• Golan T, Khvalevsky EZ, Hubert A, et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget 2015;6:24560–70.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Weiler J, et al. Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Mol Ther Nucleic Acids 2013;2:e110.
   PubMedGoogle Scholar
• Kanasty R, Dorkin JR, Vegas A, et al. Delivery materials for siRNA therapeutics. Nat Mater 2013;12:967–77.
   PubMed Web of Science ®Google Scholar
• Vorhies JS, Nemunaitis J. Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Expert Rev Anticancer Ther 2007;7:373–82.
   PubMed Web of Science ®Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003;4:346–58.
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014;15:541–55.
   PubMed Web of Science ®Google Scholar
• Young SW, Stenzel M, Yang JL. Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol 2016; 98:159–69.
   PubMed Web of Science ®Google Scholar
• Williford JM, Wu J, Ren Y, et al. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 2014;16:347–70.
   PubMed Web of Science ®Google Scholar
• Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129–38.
   PubMed Web of Science ®Google Scholar
• Esmaeili MA. Combination of siRNA-directed gene silencing with epigallocatechin-3-gallate (EGCG) reverses drug resistance in human breast cancer cells. J Chem Biol 2015;9:41–52.
   PubMedGoogle Scholar
• Dong H, Yao L, Bi W, et al. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells. J Cancer Res Ther 2015;11:717–22.
   PubMed Web of Science ®Google Scholar
• Meng H, Mai WX, Zhang H, et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 2013;7:994–1005.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang Y, Zhang W, et al. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Colloids Surf B Biointerfaces 2016;138:60–9.
   PubMed Web of Science ®Google Scholar
• Komarova NL, Boland CR. Cancer: calculated treatment. Nature 2013;499:291–2.
   PubMed Web of Science ®Google Scholar
• Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv 2017;14:65–73.
   PubMed Web of Science ®Google Scholar
• Saraswathy M, Gong S. Recent developments in the co-delivery of siRNA and small molecule anticancer drugs for cancer treatment. Mater Today 2014;17:298–306.
   Web of Science ®Google Scholar
• Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010;1805:105.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010;596:47–76.
   PubMedGoogle Scholar
• Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000;11:265–83.
   PubMed Web of Science ®Google Scholar
• Pérez-Tomás R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859–76.
   PubMed Web of Science ®Google Scholar
• Babu A, Wang Q, Muralidharan R, et al. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm 2014;11:2720–33.
   PubMed Web of Science ®Google Scholar
• Yang H, Ding R, Tong Z, et al. siRNA targeting of MDR1 reverses multidrug resistance in a nude mouse model of doxorubicin-resistant human hepatocellular carcinoma. Anticancer Res 2016;36:2675–82.
   PubMed Web of Science ®Google Scholar
• Nascimento AV, Singh A, Bousbaa H, et al. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater 2017;47:71–80.
   PubMed Web of Science ®Google Scholar
• Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011;61:250–81.
   PubMed Web of Science ®Google Scholar
• Chen WH, Lecaros RL, Tseng YC, et al. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett 2015;359:65–74.
   PubMed Web of Science ®Google Scholar
• Wang X, Liu K, Yang G, et al. Near-infrared light triggered photodynamic therapy in combination with gene therapy using upconversion nanoparticles for effective cancer cell killing. Nanoscale 2014;6:9198–205.
   PubMed Web of Science ®Google Scholar
• Xue LY, Chiu SM, Oleinick NL. Atg7 deficiency increases resistance of MCF-7 human breast cancer cells to photodynamic therapy. Autophagy 2010;6:248–55.
   PubMed Web of Science ®Google Scholar
• Kim J, Lim H, Kim S, et al. Effects of HSP27 downregulation on PDT resistance through PDT-induced autophagy in head and neck cancer cells. Oncol Rep 2016;35:2237–45.
   PubMed Web of Science ®Google Scholar
• Mao CP, Hung CF, Wu TC, et al. Immunotherapeutic strategies employing RNA interference technology for the control of cancers. J Biomed Sci 2007;14:15–29.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Ghafouri-Fard S. siRNA and cancer immunotherapy. Immunotherapy 2012;4:907–17.
   PubMed Web of Science ®Google Scholar
• Naidu MD, Mason JM, Pica RV, et al. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. J Radiat Res 2010; 51:393–404.
   PubMed Web of Science ®Google Scholar
• Higgins GS, Prevo R, Lee YF, et al. A siRNA screen of genes involved in DNA repair identifies tumour specific radiosensitisation by POLQ knockdown. Cancer Res 2010;70:2984–93.
   PubMed Web of Science ®Google Scholar
• Mehta M, Basalingappa K, Griffith JN, et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget 2016;7:64820–35.
   PubMed Web of Science ®Google Scholar
• Jin H, Gao S, Guo H, et al. Re-sensitization of radiation resistant colorectal cancer cells to radiation through inhibition of AMPK pathway. Oncol Lett 2016;11:3197–201.
   PubMed Web of Science ®Google Scholar
• Gong X, Li X, Zhou C. 81P radiation resistance induced immunity evasion by evoking PD-L1 expression. J Thorac Oncol 2016;11:S57–S166.
   Google Scholar
• Retif P, Pinel S, Toussaint M, et al. Nanoparticles for radiation therapy enhancement: the key parameters. Theranostics 2015;5:1030–44.
   PubMed Web of Science ®Google Scholar
• Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol 1986;4:244–57.
   PubMed Web of Science ®Google Scholar
• Tekedereli I, Alpay SN, Akar U, et al. Therapeutic silencing of Bcl-2 by systemically administered siRNA nanotherapeutics inhibits tumor growth by autophagy and apoptosis and enhances the efficacy of chemotherapy in orthotopic xenograft models of ER (−) and ER (+) breast cancer. Mol Ther Nucleic Acids 2013;2:e121.
   PubMedGoogle Scholar
• Shen Y, Wang J, Li Y, et al. Co-delivery of siRNA and paclitaxel into cancer cells by hyaluronic acid modified redox-sensitive disulfide-crosslinked PLGA–PEI nanoparticles. RSC Adv 2015;5:46464–79.
   Web of Science ®Google Scholar
• Creixell M, Peppas NA. Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 2012;7:367–79.
   PubMed Web of Science ®Google Scholar
• Godsey ME, Suryaprakash S, Leong KW. Materials innovation for co-delivery of diverse therapeutic cargos. RSC Adv 2013;3:24794–811.
   PubMed Web of Science ®Google Scholar
• Kang L, Gao Z, Huang W, et al. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B 2015;5:169–75.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine 2015;10:975–99.
   PubMed Web of Science ®Google Scholar
• Shim G, Kim MG, Park JY, et al. Application of cationic liposomes for delivery of nucleic acids. J Pharm Sci 2013;8:72–80.
   Google Scholar
• Bender HR, Kane S, Zabel MD. Delivery of therapeutic siRNA to the CNS using cationic and anionic liposomes. J Vis Exp 2016;113:e54106. doi: 10.3791/54106
   Web of Science ®Google Scholar
• Ko YT, Bickel U. Liposome-encapsulated polyethylenimine/oligonucleotide polyplexes prepared by reverse-phase evaporation technique. AAPS PharmSciTech 2012;13:373–8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Peng L, Mumper RJ, et al. Combinational delivery of c-Myc siRNA and nucleoside analogues in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013;34:8459–68.
   PubMed Web of Science ®Google Scholar
• Qu MH, Zeng RF, Fang S, et al. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm 2014;474:112–22.
   PubMed Web of Science ®Google Scholar
• Peng Z, Wang C, Fang E, et al. Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy. PLoS One 2014;9:e92924. doi: 10.1371/journal.pone.0092924
   PubMed Web of Science ®Google Scholar
• Yao Y, Su Z, Liang Y, et al. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int J Nanomedicine 2015;10:6185–97.
   PubMed Web of Science ®Google Scholar
• Oh HR, Jo HY, Park JS, et al. Galactosylated liposomes for targeted co-delivery of doxorubicin/vimentin siRNA to hepatocellular carcinoma. Nanomaterials 2016;6:141.
   Web of Science ®Google Scholar
• Yang T, Li B, Qi S, et al. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics 2014;4:1096–11.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Li JQ, Wang ZZ, et al. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 2014;35:5226–39.
   PubMed Web of Science ®Google Scholar
• Lecaros RLG, Huang L, Lee TC, et al. Nanoparticle delivered VEGF-A siRNA enhances photodynamic therapy for head and neck cancer treatment. Mol Ther 2016;24:106–16.
   PubMed Web of Science ®Google Scholar
• Kang SH, Cho HJ, Shim G, et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm Res 2011;28:3069–78.
   PubMed Web of Science ®Google Scholar
• Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 2008;3:761–76.
   PubMed Web of Science ®Google Scholar
• Ha J, Cho SK, Park ES, et al. Enhanced stability of hydroxyapatite-coated liposomes for ultrasound-triggered drug release. Bull Korean Chem Soc 2015;36:83–7.
   Web of Science ®Google Scholar
• Sévin DC, Sauer U. Ubiquinone accumulation improves osmotic-stress tolerance in Escherichia coli. Nat Chem Biol 2014;10:266–72.
   PubMed Web of Science ®Google Scholar
• Hernández AV, Eriksson EK, Edwards K. Ubiquinone-10 alters mechanical properties and increases stability of phospholipid membranes. Biochim Biophys Acta 2015;1848:2233–43.
   PubMed Web of Science ®Google Scholar
• Kang SN, Honga S-S, Kima S-Y, et al. Enhancement of liposomal stability and cellular drug uptake by incorporating tributyrin into celecoxib-loaded liposomes. Asian J Pharm Sci 2013;8:128–33.
   Google Scholar
• Pawar S, Shevalkar G, Vavia P. Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation. J Drug Target 2016;8:730–43.
   Web of Science ®Google Scholar
• Sharma V, Anandhakumar S, Sasidharan M. Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery. Mater Sci Eng C Mater Biol Appl 2015;56:393–400.
   PubMed Web of Science ®Google Scholar
• Namdeo A, Jain NK. Niosomal delivery of 5-fluorouracil. J Microencapsul 1999;16:731–40.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Double JA, Turton JA, et al. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm Res 1995;12:1019–24.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Double JA, Kelland LR, et al. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target 1996;3:399–409.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen J, Chen X, et al. PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides. J Mater Sci Mater Med 2008;19:607–14.
   PubMed Web of Science ®Google Scholar
• Tavano L, Muzzalupo R, Mauro L, et al. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy. Langmuir 2013;29:12638–46.
   PubMed Web of Science ®Google Scholar
• Grijalvo S, Alagia A, Puras G, et al. Cationic vesicles based on non-ionic surfactant and synthetic aminolipids mediate delivery of antisense oligonucleotides into mammalian cells. Colloids Surf B Biointerfaces 2014;119:30–7.
   PubMed Web of Science ®Google Scholar
• Rajput S, Puvvada N, Kumar BN, et al. Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm 2015;12:4214–25.
   PubMed Web of Science ®Google Scholar
• Tamura A, Nagasak Y. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. Nanomedicine (Lond) 2010;5:1089–102.
   PubMed Web of Science ®Google Scholar
• Shroff K, Vidyasagar A. Polymer nanoparticles: newer strategies towards targeted cancer therapy. J Phys Chem Biophys 2013;3:125.
   Google Scholar
• Zhang CG, Zhu WJ, Liu Y, et al. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy. Sci Rep 2016;6:23859.
   PubMed Web of Science ®Google Scholar
• Hao S, Yan Y, Ren X, et al. Candesartan-graft-polyethyleneimine cationic micelles for effective co-delivery of drug and gene in anti-angiogenic lung cancer therapy. Biotechnol Bioprocess Eng 2015;20:550–60.
   Web of Science ®Google Scholar
• Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv 2010;7:429–44.
   PubMed Web of Science ®Google Scholar
• Su WP, Cheng FY, Shieh DB, et al. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 2012;7:4269–83.
   PubMed Web of Science ®Google Scholar
• Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010;31:358–65.
   PubMed Web of Science ®Google Scholar
• Wei W, Lv PP, Chen XM. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 2013;34:3912–23.
   PubMed Web of Science ®Google Scholar
• Alinejad V, Somi MH, Baradaran B, et al. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells. Biomed Pharmacother 2016;83:229–40.
   PubMed Web of Science ®Google Scholar
• Xu C, Tian H, Sun H, et al. A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer. RSC Adv 2015;5:103380–5.
   Web of Science ®Google Scholar
• Zhu C, Jung S, Luo S, et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010;31:2408–16.
   PubMed Web of Science ®Google Scholar
• Xu M, Qian J, Suo A, et al. Co-delivery of doxorubicin and P-glycoprotein siRNA by multifunctional triblock copolymers for enhanced anticancer efficacy in breast cancer cells. J Mater Chem B 2015;3:2215–28.
   Web of Science ®Google Scholar
• Biswas S, Deshpande PP, Navarro G, et al. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials 2013;34:1289–301.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Huo S, Hardie J, et al. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv 2016;13:547–59.
   PubMed Web of Science ®Google Scholar
• Bishop CJ, Tzeng SY, Green JJ. Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA. Acta Biomater 2015;11:393–403.
   PubMed Web of Science ®Google Scholar
• Ding Y, Jiang Z, Saha K, et al. Gold nanoparticles for nucleic acid delivery. Mol Ther 2014;22:1075–83.
   PubMed Web of Science ®Google Scholar
• Guo S, Huang Y, Jiang Q, et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano 2010;4:5505–11.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Jaskula-Sztul R, Javadi A, et al. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 2012;4:7185–93.
   PubMed Web of Science ®Google Scholar
• Esteban-Fernández AB, Angell C, Soto F, et al. Acoustically propelled nanomotors for intracellular siRNA delivery. ACS Nano 2016;10:4997–5005.
   PubMed Web of Science ®Google Scholar
• Meng H, Liong M, Xia T, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010;4:4539–50.
   PubMed Web of Science ®Google Scholar
• Hanafi-Bojd MY, Jaafari MR, Ramezanian N, et al. Co-delivery of epirubicin and siRNA using functionalized mesoporous silica nanoparticles enhances in vitro and in vivo drug efficacy. Curr Drug Deliv 2015;13:1176–82.
   Web of Science ®Google Scholar
• Ma X, Zhao Y, Ng KW, et al. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery. Chemistry 2013;19:15593–603.
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee JE, Byun E, et al. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. J Control Release 2014;192:122–30.
   PubMed Web of Science ®Google Scholar
• Lee K, Oh MH, Lee MS, et al. Stabilized calcium phosphate nano-aggregates using a dopa-chitosan conjugate for gene delivery. Int J Pharm 2013;445:196–202.
   PubMed Web of Science ®Google Scholar
• Cheng X, Kuhn L. Chemotherapy drug delivery from calcium phosphate nanoparticles. Int J Nanomedicine 2007;2:667–74.
   PubMed Web of Science ®Google Scholar
• Jun W, Lin L, Yurong C, et al. Recent advances of calcium phosphate nanoparticles for controlled drug delivery. Mini Rev Med Chem 2013;13:1501–7.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Schwerbrock NM, Rogers AB, et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther 2013;21:1559–69.
   PubMed Web of Science ®Google Scholar
• Varkouhi AK, Foillard S, Lammers T, et al. SiRNA delivery with functionalized carbon nanotubes. Int J Pharm 2011;416:419–25.
   PubMed Web of Science ®Google Scholar
• Siu KS, Zhang Y, Zheng X, et al. Non-covalently functionalized of single-walled carbon nanotubes by DSPE-PEG-PEI for SiRNA delivery. Methods Mol Biol 2016;1364:151–63.
   PubMedGoogle Scholar
• Pereira S, Lee J, Rubio N, et al. Cationic liposome-multi-walled carbon nanotubes hybrids for dual siPLK1 and doxorubicin delivery in vitro. Pharm Res 2015;32:3293–308.
   PubMed Web of Science ®Google Scholar
• Kumar V, Mondal G, Slavik P, et al. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer. Mol Pharm 2015;12:1289–98.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhu X, Zhang X, et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 2010;18:1650–6.
   PubMed Web of Science ®Google Scholar
• Ma X, Nguyen KT, Borah P, et al. Functional silica nanoparticles for redox-triggered drug/ssDNA co-delivery. Adv Healthc Mater 2012;1:690–7.
   PubMed Web of Science ®Google Scholar
• Ren Y, Wang R, Gao L, et al. Sequential co-delivery of miR-21 inhibitor followed by burst release doxorubicin using NIR-responsive hollow gold nanoparticle to enhance anticancer efficacy. J Control Release 2016;28:74–86.
   Web of Science ®Google Scholar
• Wang S, Zhang J, Wang Y, et al. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy. Nanomedicine 2016;12:411–20.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang P, Chen Y, et al. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Int J Mol Med 2014;34:191–6.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao S, Ye WH, et al. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006;5:791–6.
   PubMed Web of Science ®Google Scholar
• Liang P, Wang CQ, Chen H, et al. Multi-functional heparin–biotin/heparin/calcium carbonate/calcium phosphate nanoparticles for targeted co-delivery of gene and drug. Polym Int 2015;64:647–53.
   Web of Science ®Google Scholar
• Zhou Z, Kennella C, Lee JY, et al. Calcium phosphate-polymer hybrid nanoparticles for enhanced triple negative breast cancer treatment via co-delivery of paclitaxel and miR-221/222 inhibitors. Nanomedicine 2017;2:403–10.
   Web of Science ®Google Scholar
• Zhao D, Liu CJ, Zhuo RX, et al. Alginate/CaCO3 hybrid nanoparticles for efficient codelivery of antitumor gene and drug. Mol Pharm 2012;9:2887–93.
   PubMed Web of Science ®Google Scholar